Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Acquire 557,414 Treasury Shares Worth Approximately KRW 100 Billion

Posted on May 21, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Acquire 557,414 Treasury Shares Worth Approximately KRW 100 Billion

Fact Source: Financial Supervisory Service DART / 2026-05-21

Disclosure Type: Decision on Acquisition of Treasury Shares

💡 3-Second Summary

For the purpose of stabilizing its stock price and enhancing shareholder value, Celltrion has decided to acquire 557,414 treasury shares (estimated at KRW 100 billion) through open-market buybacks on the Korea Exchange from June 8, 2026, to August 21, 2026.

📊 1. [Summary of Key Disclosure Content and Figures]

  • Class and Number of Shares to Acquire: 557,414 registered common shares
  • Estimated Acquisition Amount: KRW 100,000,071,600 (Approx. KRW 100 billion)
    • Calculation Basis: Based on the closing price on May 20, 2026 (KRW 179,400), the business day prior to the Board resolution. Actual total expenditure may vary depending on future market price fluctuations.
  • Expected Acquisition Period: From June 8, 2026, to August 21, 2026
    • Intended Holding Period: At least 6 months following the final purchase date
  • Purpose of Acquisition: Stock price stabilization and enhancement of shareholder value
  • Method of Acquisition: Direct open-market purchase on the KOSPI market
  • Entrusted Investment Broker: NH Investment & Securities Co., Ltd.
  • Daily Purchase Order Limit: 161,074 common shares
  • Treasury Stock Holdings Prior to Acquisition:
    • Shares acquired within dividendable profit limits: None
    • Other acquisitions (including appraisal rights exercised): 3,226,478 common shares (1.5% of total outstanding common shares)
  • Acquisition Restrictions: Since the Board also resolved a bonus issue on May 21, 2026, the company is legally restricted from acquiring treasury shares until the new share allocation base date (June 5, 2026). Thus, actual purchasing transactions will commence on June 8, 2026.

📈 2. [Professional Insight: What This Disclosure Means for Investors]

  • Supportive Downward Rigidity via Capital Deployment: Buying back 557,414 common shares represents a direct demand injection into the open market, which is generally anticipated to build solid downward price support for Celltrion’s stock. Controlled by a daily cap of 161,074 shares, the structural purchasing program will likely mitigate volatility by executing gradual, balanced buybacks over the two-and-a-half-month acquisition window.
  • Strategic Sequencing of Bonus Issue and Buyback Timelines: Because Celltrion resolved both the stock buyback and a bonus issue on the same day, statutory restrictions prevent treasury share purchases prior to the June 5 allotment date. Consequently, actual market buying will begin on June 8. International investors should carefully factor this delayed timeline into their near-term execution algorithms and liquidity models.
  • Strong Balance Sheet and Distributable Reserves: The KRW 100 billion allocated for this buyback represents a tiny fraction of the company’s total statutory ceiling for treasury share acquisitions (approximately KRW 4.593 trillion, calculated based on the standalone financial statements as of December 31, 2025). This low utilization rate highlights the company’s exceptional liquidity buffer and robust fundamental capacity to execute recurring shareholder return measures.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion is deploying a substantial capital shield to support its equity base. Allocating KRW 100 billion to directly retrieve 557,414 common shares from the open market highlights the board’s proactive stance on equity value stabilization. From a market structure standpoint, the concurrent scheduling of a bonus issue introduces a unique administrative sequence: the buyback remains legally locked until the June 5 stock dividend base date, meaning the buying engine officially ignites on June 8. This timing strategically deploys the KRW 100 billion cash bid right as the stock begins trading on an ex-rights adjusted basis, buffering the nominal price with direct buying volume through NH Investment & Securities. Long-term international macro allocators should value this coordinated structural design as it effectively harmonizes regulatory mechanics with active spot-market liquidity support.

📢 Disclaimer & Source Information

Source: This content has been structured and newly written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, solicitation, or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance queries or copyright-related requests, please contact us at ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) Designated as ‘Investment Warning Stock’ Due to Surge; Potential Trading Suspension on Continued Rally
Next Post: [Disclosure] Jeju Semiconductor(080220) Triggered by Extreme Surge! KRX Issues Warning Bomb, Predicting ‘Trading Suspension’ Upon Further Advance on May 22

Related Posts

[Disclosure] Samsung Biologics (207940) Sets Evaluated Price at KRW 1,221,000 for Relisting Following Corporate Division Bio & Healthcare
[Disclosure] Alteogen (196170) to Receive USD 25,000,000 (Approx. KRW 35.05B) Milestone Technical Fee from MSD for ALT-B4 Disclosures
[Disclosure] SAMSUNG BIOLOGICS(207940) Forecasts FY2025 Consolidated Revenue at KRW 5.57T Disclosures
[Disclosure] Alteogen (196170) Announces AGM Results; Re-election of CEO Park Soon-jae and Approval of All Proposed Agendas Disclosures
[Disclosure] Samsung Biologics (207940) Extends LOI Period and Confidentiality Deadline to Aug 31 for KRW 154.1B CMO Deal Disclosures
[Disclosure] Celltrion (068270) Signs Global License-in Agreement with Kobiolabs for Microbiome Intestinal Disorder Candidates Worth Up to KRW 205.2B Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme